An observational study in Wilson Disease and Generalized Epilepsy, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2021-07-16.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational
Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.
Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is the only one that started in 2010, is one of 6 observational ones, and was the 5th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:
Orphalan · Sites in China, United States, Pakistan and 1 more country
DSciLab Co., Ltd. · Sites in China
Chaohui Yu · Sites in China
Jun Li · Sites in China
Wan-Jin Chen · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Hepatolenticular Degeneration studies recruiting now, 16 (76%) set no upper age limit and 4 (19%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2010.
This study's enrollment of 13 is below the median of 72 across 35 observational studies indexed under Hepatolenticular Degeneration.
Median enrollment 18 across the 9 interventional studies, 600 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,047 studies on the registry; 502 are open to participants now.
Second Affiliated Hospital, School of Medicine, Zhejiang University has 3 studies filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
2 of the studies in Hepatolenticular Degeneration with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06650319Chaohui YuA Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease | 2026-12-30 |
| NCT07173933GeneCradle IncPhase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) | 2027-04 |
Among the 15 studies in Hepatolenticular Degeneration with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for WD patients with epilepsy in the future.
A retrospective study was performed in 13 Chinese WD patients with generalized epilepsy. Each patient was diagnosed with WD by clinical evaluation and genetic screening. Patients were given small doses of antiepileptic drugs (AEDs), followed by copper-chelation therapy when the seizures stabilized. Clinical manifestations, brain imaging changes, and treatment and outcome after a long-term follow-up were analyzed.
Each patient was diagnosed with WD by clinical evaluation and genetic screening. Patients were given small doses of antiepileptic drugs (AEDs), followed by copper-chelation therapy when the seizures stabilized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chinese WD patients with generalized epilepsy
Genetic: genetic test
Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
Number of participants with treatment stop seizures attacks
After standard treatment, the patients would stop attacks and get improved.
Time frame: 12 month
Number of participants with treatment have improved brain MRI
After standard treatment, the abnormalities of brain MRI would get better in patients.
Time frame: 12 month
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2010 to primary completion in Sep 2017, 84 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatolenticular Degeneration →
Second Affiliated Hospital, School of Medicine, Zhejiang University →